[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559504":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":48,"responsibleParty":83,"collaborators":26,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":26,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":26,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":26,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Cleveland Dental Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Articaine","EXPERIMENTAL","Inferior Alveolar Nerve block using Articaine 4% with 1:200,000 epinephrine local anesthetic",[13],"Drug: 4% Articaine with 1:200,000 epinephrine",{"label":15,"type":16,"description":17,"interventionNames":18},"Lidocaine","ACTIVE_COMPARATOR","Inferior Alveolar Nerve block using 2% lidocaine with 1:100,000 epinephrine local anesthetic",[19],"Drug: 2% lidocaine with 1:100,000 epinephrine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","4% Articaine with 1:200,000 epinephrine","Inferior Alveolar Nerve Block with 4% articaine",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"2% lidocaine with 1:100,000 epinephrine","Inferior Alveolar Nerve Block with 2% lidocaine",[15],[32,35],{"name":33,"affiliation":5,"role":34},"Ahmed A Hashem, PhD","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Waleed Elmallah, PhD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Pablo R Velazquez, Resident","CONTACT","7546108595","p.velazquez@cdiohio.org",{"name":45,"role":41,"phone":46,"phoneExt":26,"email":47},"Nelson A Rendon, Resident","9548605748","n.rendon@cdiohio.org",[49,74],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Akron","Ohio","44703","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-81.51901,41.08144,{"lat":60,"lon":59},[63,66,69,72],{"name":36,"role":41,"phone":64,"phoneExt":26,"email":65},"216-333-6695","w.elmallah@cdiohio.org",{"name":33,"role":41,"phone":67,"phoneExt":26,"email":68},"4405021591","a.hashem@cdiohio.org",{"name":70,"role":71,"phone":26,"phoneExt":26,"email":26},"Pablo Velazquez, resident","SUB_INVESTIGATOR",{"name":73,"role":71,"phone":26,"phoneExt":26,"email":26},"Nelson Rendon, resident",{"facility":5,"status":75,"city":76,"state":52,"zip":77,"country":54,"countryCode":55,"cosmosGeoPoint":78,"geoPoint":82,"contacts":26},"ACTIVE_NOT_RECRUITING","Ashtabula","44004",{"type":57,"coordinates":79},[80,81],-80.78981,41.86505,{"lat":81,"lon":80},{"type":84,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100559504","phase-1-risk-of-nerve-damage-after-administration-of-local-anesthesia-100559504",false,"NCT06564987","Risk of Nerve Damage After Administration of Local Anesthesia","Risk of Nerve Damage After Administration of an Inferior Alveolar Nerve Block Using 4% Articaine Versus 2% Lidocaine","Inclusion Criteria:\n\n* Patients with age between 18-55 years old\n* Patients need IANB\n* healthy patient\n\nExclusion Criteria:\n\n* medical conditions\n* allergies\n* medications\n* pregnancy and breastfeeding\n* inability to provide informed consent\n* specific dental or medical history.",true,"ALL","18 Years","55 Years",{"count":97,"type":98},80,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.",[104],"Inferior Alveolar Nerve Injuries","2024-08-23",{"date":107,"type":108},"2024-08-26","ACTUAL",{"date":110,"type":108},"2024-01-01",{"date":112,"type":98},"2025-03-31",{"name":5,"class":6},2]